Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial

Vascular Medicine

Volumn 8, Issue 3, 2003, Pages 191-196

  van Royen, Niels ^a   Piek, Jan J ^a   Legemate, Dink A ^a   Schaper, Wolfgang ^b   Oskam, Jacques ^b   Atasever, Bektas ^a   Voskuil, Michiel ^a   Ubbink, Dirk ^a   Schirmer, Stephan H ^c   Buschmann, Ivo ^d   Bode, Christoph ^d   Buschmann, Eva E ^d  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c RIJNLAND HOSPITAL   (Netherlands)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Angiogenesis; Arteriogenesis; Collateral circulation; Growth factors; Monocytes; Peripheral artery disease

Indexed keywords

BERLEX; PLACEBO; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ACHILLES REFLEX; ANGIOGENESIS; ARTICLE; BYPASS SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONDUCTANCE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISTANCE PERCEPTION; DOUBLE BLIND PROCEDURE; EXPERIMENTAL DESIGN; HUMAN; ILIAC ARTERY; INTERMITTENT CLAUDICATION; LASER DOPPLER FLOWMETRY; MICROANGIOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PAIN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REST; TOXICITY TESTING; TREADMILL EXERCISE; TREATMENT INDICATION; WALKING;

ARTERIAL OCCLUSIVE DISEASES; ARTERIES; BLOOD FLOW VELOCITY; COLLATERAL CIRCULATION; DOUBLE-BLIND METHOD; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERMITTENT CLAUDICATION; NEOVASCULARIZATION, PHYSIOLOGIC; RESEARCH DESIGN;

EID: 10744228257     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x03vm496oa     Document Type: Article

References (30)

1. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
2. Weitz JI, Byrne J, Clagett GP et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation 1996; 94: 3026-49.
3. Chang JK, Calligaro KD, Ryan S, Runyan D, Dougherty MJ, Stern JJ. Risk factors associated with infection of lower extremity revascularization: analysis of 365 procedures performed at a teaching hospital. Ann Vasc Surg 2003; 17: 91-96.
4. Watson HR, Belcher G, Horrocks M. Reintervention its a clinical trial endpoint after peripheral arterial bypass surgery. Br J Surg 2001; 88: 1376-81.
5. Matsi PJ, Manninen HI, Soder HK, Mustonen P, Kouri J. Percutaneous transluminal angioplasty in femoral artery occlusions: primary and long-term results in 107 claudicant patients using femoral and popliteal catheterization techniques. Clin Radiol 1995; 50: 237-44.
6. Gray BH, Sullivan TM, Childs MB, Young JR, Olin JW. High incidence of restenosis/reocclusion of stents in the percutaneous treatment of long-segment superficial femoral artery disease after suboptimal angioplasty. J Vasc Surg 1997; 25: 74-83.
7. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6: 389-95.
8. Van Royen N, Piek JJ, Buschmann I, Hoefer I, Voskuil M, Schaper W. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res 2001; 49: 543-53.
9. Hoefer IE, van Royen N, Buschmann IR, Pick JJ, Schaper W. Time course of arteriogenesis following femoral artery occlusion in the rabbit. Cardiovasc Res 2001; 49: 609-17.
10. Van Royen N, Hoefer I, Buschmann I et al. Exogenous application of transforming growth actor beta 1 stimulates arteriogenesis in the peripheral circulation. FASEB J 2002; 16: 432-34.
11. Emanueli C, Salis MB, Pinna A, Graiani G, Manni L, Madeddu P. Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 2002; 106: 2257-62.
12. Rissanen TT, Markkanen JE, Arve K et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. FASEB J 2003: 17: 100-102.
13. Buschmann IR, Hoefer IE, van Royen N et al. GM-CSF: a strong arteriogenic factor acting by amplification of monocyte function. Atherosclerosis 2001; 159: 343-56.
14. Seiler C, Pohl T, Wustmann K et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012-17.
15. Ubbink DT, Jacobs MJ, Tangelder GJ, Slaaf DW, Reneman RS. The usefulness of capillary microscopy, transcutaneous oximetry and laser Doppler fluxmetry in the assessment of the severity of lower limb ischaemia. Int J Microcirc Clin Exp 1994; 14: 34-44.
16. Lederman RJ, Mendelsohn FO, Anderson RD et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002; 359; 2053-58
17. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90: 1314-19.
18. Gottwik MG, Puschmann S, Wusten B. Myocardial protection by collateral vessels during experimental coronary ligation: a prospective study in a canine two-infarction model. Basic Res Cardiol 1984; 79: 337-43.
19. Simons M, Bonow RO, Chronos NA. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. Circulation 2000; 102: E73-86.
20. Henry TD, Annex BH, McKendall GR et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107: 1359-65.
21. Grines CL, Watkins MW, Helmer G et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002; 105: 1291-97.
22. Simons M, Annex BH, Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002; 105: 788-93.
23. Mangan DF, Wahl SM. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and proinflammatory cytokines. J Immunol 1991; 147: 3408-12.
24. Mori N, Gotoda T, Ishibashi S et al. Effects of human recombinant macrophage colony-stimulating factor on the secretion of lipoprotein lipase from macrophages. Arterioscler Thromb 1991; 11: 1315-21.
25. Shindo J, Ishibashi T, Yokoyama K et al. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in watanabe heritable hyperlipidemic rabbits. Circulation 1999; 99: 2150-56.
26. Van Royen N, Hoefer I, Bottinger M et al. Local monocyte chemoattractant protein-1 therapy increases collateral artery formation in apolipoprotein E-deficient mice but induces systemic monocytic CD11b expression, neointimal formation, and plaque progression. Circ Res 2003; 92: 218-25.
27. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001; 7: 425-29.
28. Piek JJ, van Liebergen RA, Koch KT, de Winter RJ, Peters RJ, David GK. Pharmacological modulation of the human collateral vascular resistance in acute and chronic coronary occlusion assessed by intracoronary blood flow velocity analysis in an angioplasty model. Circulation 1997; 96: 106-15.
29. Piek JJ, van Liebergen RA, Koch KT, Peters RJ, David GK. Clinical, angiographic and hemodynamic predictors of recruitable collateral flow assessed during balloon angioplasty coronary occlusion. J Am Coll Cardiol 1997; 29: 275-82.
30. Cebon J, Lieschke GJ, Bury RW, Morstyn G. The dissociation of GM-CSF efficacy from toxicity according to route of administration: a pharmacodynamic study. Br J Haematol 1992; 80: 144-50.